NCT06304285 A Study Assessing the Effects of Acupuncture in Parkinson's Disease Patients With Chronic Appendicitis
| NCT ID | NCT06304285 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of University of Science and Technology of China |
| Condition | Parkinson's Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 84 participants in total. It began in 2024-03-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The incidence of PD is high, and when the disease is serious to a certain extent, the effect of drugs to control symptoms decreases, resulting in a significant reduction in the quality of life of patients. Recent studies have found that these PD symptoms are closely related to the intestine. For several cases of PD syndrome patients complicated with chronic appendicitis, our research group conducted acupuncture on points related to constipation and chronic appendicitis, and found that constipation and related motor symptoms of patients could be significantly improved. Clinical studies have shown that acupuncture also has a certain therapeutic effect on non-motor symptoms of Parkinson's disease, such as anxiety and depression, decreased olfactory function, sleep disorders, constipation, early skeletal muscle pain, cognitive dysfunction, etc., which can delay the progression of the disease and improve the quality of life of patients. Starting from intestinal acupuncture, this project further clarified the role of acupuncture treatment in the comprehensive treatment of PD
Eligibility Criteria
Inclusion Criteria: * Patients presenting with bradykinesia, combined with resting tremor and/or myotonia. * Appendix CT suggested chronic appendicitis evaluated by two experienced experts. * All subjects and their guardians give informed consent to the content of this study and sign informed consent. * Normal coagulation function. * If the patient had taken oral anti-PD drugs, it had been stable for at least 2 weeks at enrollment. Exclusion Criteria: * Treatment with dopamine blockers or dopamine depleters in doses and time courses consistent with drug-induced parkinsonism. * Neuroimaging examination of presynaptic dopaminergic system function was normal. * Patients who had suffered severe brain trauma or underwent complex craniotomy within 5 years prior to enrollment. * Cognitive disorders that are not on the Parkinson's spectrum, such as Alzheimer's disease, frontotemporal dementia, and Niemann-Pick disease, have been diagnosed. * People diagnosed with severe neuropsychiatric disorders (epilepsy, bipolar disorder, major depressive episode, etc.) according to DSM-V. * Complicated with serious systemic diseases, disorders of consciousness, stroke, serious coronary heart disease, diabetes, liver and kidney diseases, and serious visual and hearing disorders. * Patients with severe organic or functional dysphagia;Those who were deemed by the researcher to be unable to complete the visit and auxiliary examination as required by the study protocol.
Contact & Investigator
Yuhua Chen, M.M.S.
STUDY CHAIR
The First Affiliated Hospital of University of Science and Technology of China
Frequently Asked Questions
Who can join the NCT06304285 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 70 Years, studying Parkinson's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06304285 currently recruiting?
Yes, NCT06304285 is actively recruiting participants. Contact the research team at yh1215@mail.ustc.edu.cn for enrollment information.
Where is the NCT06304285 trial being conducted?
This trial is being conducted at Hefei, China.
Who is sponsoring the NCT06304285 clinical trial?
NCT06304285 is sponsored by The First Affiliated Hospital of University of Science and Technology of China. The principal investigator is Yuhua Chen, M.M.S. at The First Affiliated Hospital of University of Science and Technology of China. The trial plans to enroll 84 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.